Leukemia Stocks List

Leukemia Stocks Recent News

Date Stock Title
May 2 SYRS Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
May 2 TEVA Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
May 2 TEVA Q1 2024 Corcept Therapeutics Inc Earnings Call
May 2 PSTX Xyphos and Poseida to develop allogeneic cell therapies for cancer
May 2 NEO NeoGenomics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
May 2 TEVA Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...
May 1 CRDF Cardiff Oncology Q1 2024 Earnings Preview
May 1 KURA Kura Oncology Q1 2024 Earnings Preview
May 1 PSTX Poseida gains on cell therapy pact with Astellas
May 1 SYRS Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
May 1 PSTX Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
May 1 INO INOVIO Reports Inducement Grants Under Inducement Plan
May 1 PSTX Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
May 1 NEO NeoGenomics Inc (NEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ...
Apr 30 NEO NeoGenomics, Inc. (NEO) Q1 2024 Earnings Call Transcript
Apr 30 NEO Where NeoGenomics Stands With Analysts
Apr 30 TEVA Novo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patents
Apr 30 NEO Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings
Apr 30 NEO NeoGenomics Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows
Apr 30 NEO NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
Leukemia

Leukemia, also spelled leukaemia, is a group of cancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells. These white blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and bruising problems, feeling tired, fever, and an increased risk of infections. These symptoms occur due to a lack of normal blood cells. Diagnosis is typically made by blood tests or bone marrow biopsy.The exact cause of leukemia is unknown. A combination of genetic factors and environmental (non-inherited) factors are believed to play a role. Risk factors include smoking, ionizing radiation, some chemicals (such as benzene), prior chemotherapy, and Down syndrome. People with a family history of leukemia are also at higher risk. There are four main types of leukemia—acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML)—as well as a number of less common types. Leukemias and lymphomas both belong to a broader group of tumors that affect the blood, bone marrow, and lymphoid system, known as tumors of the hematopoietic and lymphoid tissues.Treatment may involve some combination of chemotherapy, radiation therapy, targeted therapy, and bone marrow transplant, in addition to supportive care and palliative care as needed. Certain types of leukemia may be managed with watchful waiting. The success of treatment depends on the type of leukemia and the age of the person. Outcomes have improved in the developed world. The average five-year survival rate is 57% in the United States. In children under 15, the five-year survival rate is greater than 60 to 85%, depending on the type of leukemia. In children with acute leukemia who are cancer-free after five years, the cancer is unlikely to return.In 2015, leukemia was present in 2.3 million people and caused 353,500 deaths. In 2012 it newly developed in 352,000 people. It is the most common type of cancer in children, with three quarters of leukemia cases in children being the acute lymphoblastic type. However, about 90% of all leukemias are diagnosed in adults, with AML and CLL being most common in adults. It occurs more commonly in the developed world.

Browse All Tags